GlassScriptPhysician profile
Andrei Rebarber
NPI 1598723272
$4,828.20
in general payments reported to CMS, 2019-2025
13 companies · $263 in 2025
The $263 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $215 · 2021: $4,036 · 2022: $122 · 2023: $168 · 2024: $23.86 · 2025: $263.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $455.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $454.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cytyc Prenatal Products Corp. | $4,000.00 | 2021 | |
| Celularity INC. | $199.00 | 2019 | |
| Samsung Hme America, INC. | $122.77 | 2025 | |
| Biogen, INC. | $114.66 | 2025 | Zurzuvae |
| Ge Healthcare | $99.80 | 2023 | |
| Evofem Biosciences, INC. | $79.59 | 2021-2024 | |
| Scynexis, INC. | $69.02 | 2022 | |
| Shield Therapeutics INC | $42.90 | 2023 | Accrufer |
| Sanofi Pasteur INC. | $25.73 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $25.16 | 2023 | |
| Agile Therapeutics, INC. | $17.18 | 2022 | |
| Merck Sharp & Dohme LLC | $16.28 | 2022 | |
| Therapeuticsmd, INC. | $16.11 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrei Rebarber listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.